Stempeutics Gets Stem Cell Patent in China (Chinese Application Number: CN201080053627) for its Novel Stem Cell Drug 'Stempeucel'

BANGALORE, India, April 27, 2015 /PRNewswire/

**The First Company in the World to be Granted a Process Patent by the State Intellectual Property Office of China (SIPO) For a Stem Cell Drug Based on Pooling Technology**

**- A New Treatment Which Offers Hope for Patients Suffering From Critical Limb Ischemia (CLI)**

**- About 20% of Elderly Urban Chinese Suffer From Peripheral Arterial disease (PAD) and the Prevalence in Women is Substantially Higher Than in Men. CLI is a Progressive Form of PAD**

**- Smokers are at High Risk of Contracting PAD**

Stempeutics Research, a group company of Manipal Education and Medical Group and a Joint Venture with Cipla Group, announced today that the State Intellectual Property Office of China(SIPO) granted a process patent for its novel stem-cell based drug Stempeucel. Stempeucel will initially be used for the treatment of CLI and is a breakthrough treatment option which directly addresses the root cause of the disease, unlike other drugs which typically treat the symptoms and not the disease itself.

Critical Limb Ischemia (CLI) is a progressive form of peripheral arterial disease, which blocks the arteries in the lower extremities, resulting into reduction of the blood flow. It is a debilitating disease which affects patients with severe pain in the feet or toes. Insufficient supply of blood flow results into the development of sores and wounds in legs and feet. If left untreated, patients may finally have to undergo amputation of the affected limb as the last treatment option. In China, the most common current treatments for CLI are characterized by high rates of primary amputations, multiple procedures and high rates of procedure-related complications. In such cases, the disease not only affects the quality of life but also increases the economic burden of patients.

Stempeucel is derived from allogeneic pooled mesenchymal stromal cells extracted from the bone marrow of healthy, adult voluntary donors. The company's proprietary pooling approach allows an efficient manufacturing process with minimum wastage of resources in order to provide the product at an affordable cost to patients. This approach also allows more than one million patient doses from a single set of master cell banks, which is unique in regenerative medicine. The proprietary technology allows Stempeucel to extend the therapeutic potential of the drug across multiple disease categories.

Commenting on the patent granted by SIPO, **Mr B N Manohar, CEO of Stempeutics,** said, "Stempeutics has taken an aggressive, focused and well thought-out scientific approach to understand the biology of human adult stem cells, and to harness the potential of these cells for the treatment of CLI. The efforts are realized through innovative technologies and ideas, cutting edge R&D, patentable process development, large scale manufacturing and effective clinical trial design. We believe that the Stempeucel product is a game-changer, offering an advanced therapeutic treatment to millions of patients suffering from this dreadful disease."

**Mr Chandru Chawla, Head Cipla New Ventures,** said, "China has a high prevalence of diabetes and consequently many suffer from ischaemic limb condition. The patent grant in China is yet another important milestone after the grant of the patent in the United States."

Stempeutics has already submitted its application to the Drug Controller General of India (DCGI) to obtain marketing authorisation approval for Stempeucel. The availability of the product in the market is subjected to DCGI approvals.

**About Stempeutics**

Stempeutics is an advanced clinical stage Biotech Company based out of Bangalore. It was founded by Manipal Education and Medical Group (MEMG) in 2006 and later entered into a strategic alliance with Cipla in 2009. Stempeutics' strength lies in developing innovative stem cell products by nurturing cutting edge research and clinical applications through dedicated efforts of its highly qualified team. Its goal is to develop novel stem cell drugs addressing major unmet medical needs with an India first global next approach.

**About Manipal Education and Medical Group (MEMG)**

MEMG is one of the leaders in the country in the field of education and healthcare services, with a global footprint. MEMG, through its subsidiaries, provides education and healthcare services in India and internationally. It manages universities and professional institutions, including medical colleges, teaching hospitals, and medical science and technology institutions through which it provides bachelors' and master's degree programs in various streams. Manipal Education and Medical Group International India Pvt. Ltd. was founded in 1953 and is based in Bengaluru, India with education colleges and campuses inAntigua, Dubai, Malaysia, and Nepal.

**About Cipla Limited**

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For more than 70 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Our portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla's emphasis on access for patients was recognised globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than one dollar a day and thereby treating many millions of patients since 2001.

Cipla's research and development focuses on developing innovative products and drug delivery systems and has given Indiaand the world many 'firsts' for instance Triomune. In a tightly regulated environment, the company's manufacturing facilities have approvals from all the main regulators including USFDA, UKMHRA, WHO, MCC, ANVISA, and PMDA which means the company provides one universal standard both domestically and internationally.

**Stempeutics Research Media Contact:**

Vijayaraghavan
Corporate Communications
Mobile No: +91 9535688118
E-mail id: vijaya.raghavan@stempeutics.com
[http://www.stempeutics.com](http://www.stempeutics.com/)

**Cipla Media Contacts:**

Charlotte Chunawala
Corporate Communications
Mobile: +91-7506257377
E-mail id: charlotte.chunawala@cipla.com

Pallavi Golar
Corporate Communications
Mobile: +91-9833641788
E-mail id: pallavi.golar@cipla.com